These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31682087)

  • 1. Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis.
    Keller CW; Ruck T; McHugh D; Pfeuffer S; Gross CC; Korsukewitz C; Melzer N; Klotz L; Meuth SG; Münz C; Nimmerjahn F; Wiendl H; Lünemann JD
    Ann Clin Transl Neurol; 2019 Dec; 6(12):2586-2594. PubMed ID: 31682087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
    Arroyo R; Bury DP; Guo JD; Margolin DH; Melanson M; Daizadeh N; Cella D
    Mult Scler; 2020 Jul; 26(8):955-963. PubMed ID: 31144568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
    Alcalá C; Gascón F; Pérez-Miralles F; Domínguez JA; Gil-Perotín S; Casanova B
    J Neurol; 2019 Mar; 266(3):726-734. PubMed ID: 30661133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.
    Lin TS; Flinn IW; Modali R; Lehman TA; Webb J; Waymer S; Moran ME; Lucas MS; Farag SS; Byrd JC
    Blood; 2005 Jan; 105(1):289-91. PubMed ID: 15217834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series.
    Notas K; Papadaki E; Orologas A; Moschou M; Kimiskidis VK
    Mult Scler Relat Disord; 2020 Feb; 38():101517. PubMed ID: 31751858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
    Wiendl H; Carraro M; Comi G; Izquierdo G; Kim HJ; Sharrack B; Tornatore C; Daizadeh N; Chung L; Jacobs AK; Hogan RJ; Wychowski LV; Van Wijmeersch B;
    Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31662412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
    J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.
    Frau J; Coghe G; Lorefice L; Fenu G; Musu L; Cocco E
    J Neurol; 2019 Jun; 266(6):1405-1411. PubMed ID: 30863891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF.
    Möhn N; Pfeuffer S; Ruck T; Gross CC; Skripuletz T; Klotz L; Wiendl H; Stangel M; Meuth SG
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31826986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS.
    Akgün K; Kretschmann N; Haase R; Proschmann U; Kitzler HH; Reichmann H; Ziemssen T
    Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e555. PubMed ID: 31119188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
    Hyun JW; Kim Y; Kim G; Kim SH; Kim HJ
    Mult Scler; 2020 May; 26(6):659-667. PubMed ID: 30912689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis.
    Signoriello E; D'Amico A; Fratta M; Ugga L; Altobelli C; Conchiglia G; Barbarulo AM; Di Pietro A; Anastasio P; Rossi F; Lus G
    Mult Scler Relat Disord; 2020 Feb; 38():101518. PubMed ID: 31778927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
    Vavasour IM; Tam R; Li DK; Laule C; Taylor C; Kolind SH; MacKay AL; Javed A; Traboulsee A
    Mult Scler; 2019 May; 25(6):811-818. PubMed ID: 29663845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab in multiple sclerosis: an update.
    Gross RH; Krieger S
    Neurodegener Dis Manag; 2015; 5(3):225-32. PubMed ID: 26107321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
    Whiteside D; Barth S; Datta A; Trip SA
    Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
    Arroyo González R; Kita M; Crayton H; Havrdova E; Margolin DH; Lake SL; Giovannoni G;
    Mult Scler; 2017 Sep; 23(10):1367-1376. PubMed ID: 27885061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center.
    di Ioia M; Di Stefano V; Farina D; Di Tommaso V; Travaglini D; Pietrolongo E; Sensi SL; Onofrj M; De Luca G
    Mult Scler Relat Disord; 2020 Feb; 38():101504. PubMed ID: 31733426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.